Αρχική / Ιατρική Εκπαίδευση / Κλινικές Δοκιμές

Κλινικές Δοκιμές

 

Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?

Perysinakis I, Aggeli C, Kaltsas G, Zografos GN.
Hormones (Athens). 2016 Jan 6. doi: 10.14310/horm.2002.1636. [Epub ahead of print] Review.

Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects.

Koumarianou A, Kaltsas GKulke MH, Oberg K, Strosberg JR, Spada F, Galdy S, Barberis M, Fumagalli C, Berruti A, Fazio N.
Neuroendocrinology. 2015;101(4):274-88. doi: 10.1159/000430816. Epub 2015 Apr 29.

Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.

Kamp K, Gumz B, Feelders RA, Kwekkeboom DJ, Kaltsas G, Costa FP, de Herder WW.
Endocr Relat Cancer. 2013 Oct 14;20(6):825-31. doi: 10.1530/ERC-13-0254. Print 2013 Dec.

Bevacizumab plus temozolomide: a novel treatment option for advanced neuroendocrine tumors?

Koumarianou A, Kaltsas G.
J Clin Oncol. 2013 Mar 1;31(7):975-6. doi: 10.1200/JCO.2012.45.7523. Epub 2013 Jan 28. No abstract available.

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours.

Koumarianou A, Antoniou S, Kanakis G, Economopoulos N, Rontogianni D, Ntavatzikos A, Tsavaris N, Pectasides D, Dimitriadis G, Kaltsas G.
Endocr Relat Cancer. 2012 Jan 9;19(1):L1-4. doi: 10.1530/ERC-11-0287. Print 2012 Feb. No abstract available.

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group.
Lancet. 2011 Dec 10;378(9808):2005-12. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25.

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.

Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R, Britton KE, Grossman AB.
J Clin Endocrinol Metab. 2001 Feb;86(2):895-902.

The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors.

Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM.
J Clin Endocrinol Metab. 1998 Dec;83(12):4233-8.